GLP-1 RA antiobesity medications: Predictions for the future

Author(s):

Richard Payerchin

Key Takeaways

GLP-1 RA drugs represent a major advancement in obesity treatment, indicating a paradigm shift in managing the condition.
New pharmacological options for obesity are expected to emerge soon, enhancing treatment possibilities.
The high cost of GLP-1 RA drugs is a significant barrier, necessitating efforts to reduce prices for broader accessibility.
Dr. Robert Kushner, an expert in obesity and nutrition, underscores the importance of cost reduction based on his clinical experience.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

GLP-1 RA drugs are an important step in changing the treatment of obesity. There is a paradigm shift in thinking about obesity, and new drugs will come in a relatively short period of time. Meanwhile, “the cost clearly has to come down,” said Robert Kushner, MD, an expert researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.